Onxeo Strengthens AsiDNA™ Patent Protection in Europe

  • Composition of matter patent to be granted in Europe covering AsiDNA™ and more precisely the part related to its DNA sequence until 2027
  • Any product including this specific DNA sequence will be within the scope of this patent
  • AsiDNA™’s intellectual property will now be protected by 8 complementary patent families worldwide 

Paris (France), Copenhagen (Denmark) Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced having received communication from the European Patent Office (EPO) informing its intention to grant a new patent covering especially the particular nucleic acid molecule comprised within AsiDNA™, Onxeo’s first-in-class signal-interfering (siDNA) product candidate in the European countries.

“With the addition of this patent, AsiDNA™’s patent family will include 8 complementary patents worldwide, increasing the drugs patent protection further. The grant is another step in bringing AsiDNA™ to the patients in need and we look forward to initiating the Phase I study, which is planned for 2017,” said Judith Greciet, CEO of Onxeo.

This new patent will considerably strengthen the industrial property around AsiDNA™, by protecting the particular double-stranded DNA molecule of the drug. By covering any products conjugated or including said DNA molecule, this new patent protects AsiDNA™ as such but also derivatives thereof sharing the same DNA sequence.

The IP estate related to AsiDNA™ consists of eight worldwide patent families, covering its technology platform, its products conjugated or not, and their therapeutic utilization as a monotherapy or in combination with radiotherapy, hyperthermia or chemotherapy as well as their method of administration and the potential biomarkers predicting the response to a therapy with AsiDNA™ and/or other related products offering a protection on the product AsiDNA™ as such until 2031.

Download PDF